JTK-109 explained

Drug Name:

JTK-109

C:

37

H:

33

Cl:

1

F:

1

N:

3

O:

4

Iupac Name:

2-[4-[[2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)phenyl]methoxy]-2-fluorophenyl]-1-cyclohexylbenzimidazole-5-carboxylic acid| CAS_number = 480462-62-2| ChEMBL = 210297| DrugBank = | ChemSpiderID = 9860746| PubChem = 11686018| UNII = BJA28665XS | smiles = C1CCC(CC1)N2C3=C(C=C(C=C3)C(=O)O)N=C2C4=C(C=C(C=C4)OCC5=C(C=CC(=C5)N6CCCC6=O)C7=CC=C(C=C7)Cl)F| StdInChI= 1S/C37H33ClFN3O4/c38-26-11-8-23(9-12-26)30-15-13-28(41-18-4-7-35(41)43)19-25(30)22-46-29-14-16-31(32(39)21-29)36-40-33-20-24(37(44)45)10-17-34(33)42(36)27-5-2-1-3-6-27/h8-17,19-21,27H,1-7,18,22H2,(H,44,45)| StdInChIKey = NIBYCXOKANETJM-UHFFFAOYSA-N}}

JTK-109 is an antiviral drug which acts as a NS5B RNA-dependent RNA polymerase inhibitor. It was initially developed for the treatment of Hepatitis C, but also shows activity against caliciviruses such as norovirus.^{[1] [2] [3] [4]}

References

}

Notes and References

1. Hirashima S, Suzuki T, Ishida T, Noji S, Yata S, Ando I, Komatsu M, Ikeda S, Hashimoto H . Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109 . Journal of Medicinal Chemistry . 49 . 15 . 4721–4736 . July 2006 . 16854079 . 10.1021/jm060269e .
2. Hirashima S, Oka T, Ikegashira K, Noji S, Yamanaka H, Hara Y, Goto H, Mizojiri R, Niwa Y, Noguchi T, Ando I, Ikeda S, Hashimoto H . Further studies on hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors toward improved replicon cell activities: benzimidazole and structurally related compounds bearing the 2-morpholinophenyl moiety . Bioorganic & Medicinal Chemistry Letters . 17 . 11 . 3181–3186 . June 2007 . 17383878 . 10.1016/j.bmcl.2007.03.027 .
3. Netzler NE, Enosi Tuipulotu D, Eltahla AA, Lun JH, Ferla S, Brancale A, Urakova N, Frese M, Strive T, Mackenzie JM, White PA . Broad-spectrum non-nucleoside inhibitors for caliciviruses . Antiviral Research . 146 . 65–75 . October 2017 . 28757394 . 10.1016/j.antiviral.2017.07.014 .
4. Netzler NE, Enosi Tuipulotu D, White PA . Norovirus antivirals: Where are we now? . Medicinal Research Reviews . 39 . 3 . 860–886 . May 2019 . 30584800 . 10.1002/med.21545 . 7168425 .